Express Pharma

Ocugen announces positive results for COVID-19 vaccine trial for children aged two-18 years

Ocugen’s partner Bharat Biotech’s phase-II/III study of Covaxin (BBV152) in 526 children showed safety, efficacy, and superior response to that shown in adults

0 281

Ocugen today announced the publication of positive paediatric phase-II/III study results in children aged two-18 years for the COVID-19 vaccine Covaxin in The Lancet Infectious Diseases. Covaxin is developed and manufactured by Ocugen’s partner Bharat Biotech, and is under clinical investigation by Ocugen in the US for use in adults aged 18 years and older, Ocugen notified in a statement.

The Lancet article, entitled “Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged two-18 years: interim data from an open-label, non-randomised, age de-escalation phase-II/III study,” which was authored by Dr Krishna Mohan Vadrevu, Siddharth Red